This article is a correction to:
A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease
Elizabeth A. Spencer1Marla C. Dubinsky1Michael A. Kamm2Maria Chaparro3Paolo Gionchetti4,5Fernando Rizzello4,5Javier P. Gisbert3Emily K. Wright2Julien D. Schulberg2Amy L. Hamilton2Dermot P. B. McGovern6
Thierry Dervieux7*- 1Division of Gastroenterology, Icahn School of Medicine Mount Sinai, New York, NY, United States
- 2St Vincent’s Hospital and The University of Melbourne, Melbourne, VIC, Australia
- 3Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
- 4IRCCS Azienda Ospedaliero-Universitaria di Bologna Italy, Bologna, Italy
- 5DIMEC University of Bologna-Italy, Bologna, Italy
- 6F. Widjaja Inflammatory Bowel Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
- 7Research and Development, Prometheus Laboratories, San Diego, CA, United States
By Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB and Dervieux T (2024) Front. Immunol. 15:1342477. doi: 10.3389/fimmu.2024.1342477
In the published article, there was an error. In Table 1, the percentage of HLA DQA1*05 carriage for “all cohort” was incorrect and was corrected to 40% (168/415).
In the Abstract, and Results, section 3.2. Impact of PPF of PK origin on Immune response during treatment, there was an error in the p value reported: “Overall, each incremental PPF of PK origin resulted in a 2-fold (OR=2.16, 95%CI: 1.7-2.7; p<0.11) higher likelihood of antidrug antibody formation”.
The corrected sentence appears below:
“Overall, each incremental PPF of PK origin resulted in a 2-fold (OR=2.16, 95%CI: 1.7-2.7; p<0.01) higher likelihood of antidrug antibody formation”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: drug response, tumor necrosis factor, clearance, inflammatory bowel disease, pharmacogenetic
Citation: Spencer EA, Dubinsky MC, Kamm MA, Chaparro M, Gionchetti P, Rizzello F, Gisbert JP, Wright EK, Schulberg JD, Hamilton AL, McGovern DPB and Dervieux T (2024) Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α. Front. Immunol. 15:1383704. doi: 10.3389/fimmu.2024.1383704
Received: 07 February 2024; Accepted: 16 February 2024;
Published: 27 February 2024.
Edited and Reviewed by:
Michael Tovey, Svar Life Science, FranceCopyright © 2024 Spencer, Dubinsky, Kamm, Chaparro, Gionchetti, Rizzello, Gisbert, Wright, Schulberg, Hamilton, McGovern and Dervieux. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thierry Dervieux, tdervieux@prometheulabs.com